Gamida Cell 過去の業績
過去 基準チェック /06
Gamida Cell's earnings have been declining at an average annual rate of -12.1%, while the Biotechs industry saw earnings growing at 15% annually. Revenues have been growing at an average rate of 102.5% per year.
主要情報
-12.1%
収益成長率
25.2%
EPS成長率
| Biotechs 業界の成長 | 17.0% |
| 収益成長率 | 102.5% |
| 株主資本利益率 | n/a |
| ネット・マージン | -2,318.0% |
| 前回の決算情報 | 31 Mar 2024 |
最近の業績更新
Recent updates
Gamida Cell shares slide after stock offering
Sep 27Gamida appoints Emergent’s former head of vaccines as new CEO
Sep 19Gamida Cell Q2 2022 Earnings Preview
Aug 12Gamida stock rises 13% as FDA grants priority review to stem cell therapy omidubicel
Aug 01Does Gamida Cell (NASDAQ:GMDA) Have A Healthy Balance Sheet?
Feb 23
Gamida Cell: Recapping A Tough Year
Nov 02Gamida Cell (NASDAQ:GMDA) Has Debt But No Earnings; Should You Worry?
Nov 02収支内訳
Gamida Cell の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 31 Mar 24 | 3 | -62 | 53 | 18 |
| 31 Dec 23 | 2 | -63 | 45 | 24 |
| 30 Sep 23 | 1 | -77 | 44 | 33 |
| 30 Jun 23 | 0 | -93 | 38 | 38 |
| 31 Mar 23 | 0 | -80 | 35 | 40 |
| 31 Dec 22 | 0 | -79 | 32 | 43 |
| 30 Sep 22 | 0 | -80 | 32 | 45 |
| 30 Jun 22 | 0 | -86 | 36 | 47 |
| 31 Mar 22 | 0 | -91 | 37 | 50 |
| 31 Dec 21 | 0 | -90 | 37 | 50 |
| 30 Sep 21 | 0 | -87 | 37 | 48 |
| 30 Jun 21 | 0 | -79 | 31 | 46 |
| 31 Mar 21 | 0 | -70 | 25 | 42 |
| 31 Dec 20 | 0 | -62 | 22 | 39 |
| 30 Sep 20 | 0 | -55 | 18 | 37 |
| 30 Jun 20 | 0 | -50 | 17 | 34 |
| 31 Mar 20 | 0 | -29 | 17 | 32 |
| 31 Dec 19 | 0 | -34 | 17 | 31 |
| 30 Sep 19 | 0 | -42 | 16 | 27 |
| 30 Jun 19 | 0 | -42 | 14 | 25 |
| 31 Mar 19 | 0 | -61 | 14 | 24 |
| 31 Dec 18 | 0 | -53 | 12 | 22 |
| 30 Sep 18 | 0 | -36 | 9 | 21 |
| 30 Jun 18 | 0 | -30 | 7 | 20 |
| 31 Mar 18 | 0 | -22 | 5 | 16 |
| 31 Dec 17 | 0 | -19 | 4 | 15 |
質の高い収益: GMDA.Q is currently unprofitable.
利益率の向上: GMDA.Q is currently unprofitable.
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: GMDA.Q is unprofitable, and losses have increased over the past 5 years at a rate of 12.1% per year.
成長の加速: Unable to compare GMDA.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable
収益対業界: GMDA.Q is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
株主資本利益率
高いROE: GMDA.Q's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.